episil® oral liquid is a lipid-based fluid developed for the management and relief of pain associated with oral lesions of various aetiologies such as oral mucositis, a painful side effect of cancer therapies. After administration, and in contact with small quantities of saliva present in the oral cavity, the lipid mixture self-assembles to form a robust protective lipid membrane that strongly adheres to the oral mucosa, and soothes painful ulcerations.
episil® oral liquid is based on Camurus’ FluidCrystal® topical bioadhesive technology, and has been clinically proven to provide effective and rapid oral pain relief that lasts for up to 8 hours. episil® liquid helps patients to maintain their quality of life while undergoing cancer treatment.
For more information, see www.episil.ne